Characterization of a monoclonal antibody that binds to both gp120 and gp41

References

• 1 Chuang GY, Acharya P, Schmidt SD et al. Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains. J. Virol. 87(18), 10047–10058 (2013).
  Medline CASGoogle Scholar
• 2 Doria-Rose NA, Altae-Tran HR, Roark RS et al. Mapping polyclonal HIV-1 antibody responses via next-generation neutralization fingerprinting. PLoS Pathog. 13(1), 1006148 (2017).
  Google Scholar
• 3 Liao HX, Lynch R, Zhou T et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496(7446), 469–476 (2013).
  Medline CASGoogle Scholar
• 4 Mascola JR. The cat and mouse of HIV-1 antibody escape. PLoS Pathog. 5(9), 1000592 (2009).
  Google Scholar
• 5 Rudicell RS, Kwon YD, Pegu A et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J. Virol. 88(21), 12669–12682 (2014).
  MedlineGoogle Scholar
• 6 Sun Z, Yan L, Tang J et al. Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies. Virus Res. 243, 75–82 (2018).
  Medline CASGoogle Scholar
• 7 Sun Z, Lu S, Yang Z et al. Isolation and characterization of an HIV-1 envelope glycoprotein-specific B-cell from an immortalized human naive B-cell library. J. Gen. Virol. 98(4), 791–798 (2017).
  Medline CASGoogle Scholar
• 8 Sun Z, Li J, Hu X, Shao Y, Zhang MY. Reconstitution and characterization of antibody repertoires of HIV-1-infected “elite neutralizers.” Antiviral Res. 118, 1–9 (2015).
  MedlineGoogle Scholar
• 9 Wang K, Tomaras GD, Jegaskanda S et al. Monoclonal antibodies, derived from humans vaccinated with the RV144 HIV vaccine containing the HVEM binding domain of herpes simplex virus (HSV) glycoprotein D, neutralize hsv infection, mediate antibody-dependent cellular cytotoxicity, and protect mice from ocular challenge with HSV-1. J. Virol. 91(19), pii:e00411-17 (2017).
  Google Scholar
• 10 Pace CS, Song R, Ochsenbauer C et al. Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1. Proc. Natl Acad. Sci. USA 110(33), 13540–13545 (2013).
  Medline CASGoogle Scholar
• 11 Walker L, Wilks D, O'Brien J, Habeshaw J, Dalgleish A. Localized conformational changes in the N-terminal domain of CD4 identified in competitive binding assay of monoclonal antibodies and HIV-1 envelope glycoprotein. AIDS Res. Hum. Retroviruses 8(6), 1083–1090 (1992).
  Medline CASGoogle Scholar
• 12 Yang Z, Li J, Liu Q et al. Identification of Non-HIV immunogens that bind to germline b12 predecessors and prime for elicitation of cross-clade neutralizing HIV-1 antibodies. PLoS ONE 10(5), 0126428 (2015).
  Google Scholar
• 13 Lu S, Sun Z, Zhang MY. Generation of immortalized human naïve B cell libraries by optimized EBV transformation. J. Med. Discov. 2(1), 1–18 (2016).
  Google Scholar
• 14 Yan L, Liu L, Wang Y et al. Broadly neutralizing antibodies(BNAbs): templates for HIV-1 vaccine design. J. Med. Discov. 2(4), doi:10.24262/jmd.2.4.17039 (2017).
  Google Scholar
• 15 Li D, Gong R, Zheng J, Chen X, Dimitrov DS, Zhao Q. Engineered antibody CH2 domains binding to nucleolin: isolation, characterization and improvement of aggregation. Biochem. Biophys. Res. Commun. 485(2), 446–453 (2017).
  Medline CASGoogle Scholar
• 16 Li W, Yang H, Dimitrov DS. Identification of high-affinity anti-CD16A allotype-independent human antibody domains. Ex. Mol. Pathol. 101(2), 281–289 (2016).
  Medline CASGoogle Scholar
• 17 Zhu Z, Qin HR, Chen W et al. Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies. J. Virol. 85(21), 11401–11408 (2011).
  Medline CASGoogle Scholar
• 18 Zhou T, Xu L, Dey B et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445(7129), 732–737 (2007).
  Medline CASGoogle Scholar
• 19 Sun Z, Lu S, Yang Z, Li J, Zhang MY. Construction of a recombinant full-length membrane associated IgG library. Virus Res. 238, 156–163 (2017).
  Medline CASGoogle Scholar
• 20 Georgiev IS, Rudicell RS, Saunders KO et al. Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline. J. Immunol. 192(3), 1100–1106 (2014).
  Medline CASGoogle Scholar
• 21 Euler Z, Bunnik EM, Burger JA et al. Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic. J. Virol. 85(14), 7236–7245 (2011).
  Medline CASGoogle Scholar
• 22 Li Y, Svehla K, Louder MK et al. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J. Virol. 83(2), 1045–1059 (2009).
  Medline CASGoogle Scholar
• 23 Cheng HD, Grimm SK, Gilman MS et al. Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site. JCI Insight 3(5), pii:97018 (2018).
  Google Scholar
• 24 Walker LM, Burton DR. Passive immunotherapy of viral infections: ‘super-antibodies’ enter the fray. Nat. Rev. Immunol. 18(5), 297–308 (2018).
  Medline CASGoogle Scholar
• 25 Teijaro JR, Burton DR. Taking down defenses to improve vaccines. Science 359(6373), 277–278 (2018).
  Medline CASGoogle Scholar